Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1942 adjunctive therapy in mild to moderate Alzheimer's disease dementia
2023-504017-79-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) comparing MK-1942 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoints: Change from baseline in ADAS-Cog11 score at Week 12, Number of participants experiencing adverse events and 1 more. Started Feb 2023; status: completed.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-504017-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504017-79-00.